The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Enclomiphene

Enclomiphene Citrate · Androxal · Trans-Clomiphene

C
Animal replicated
Off-labelSERMSelective Estrogen Receptor ModulatorSmall Molecule
RouteOralGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
Trans-Isomer of Clomiphene — SERM — Selective Estrogen Receptor Modulator — FDA Not Approved — Secondary Hypogonadism — SERM, Selective Estrogen Receptor Modulator, Small Molecule.
Why people use it
Used primarily for hormonal support and sexual health.
If you only read one thing

Enclomiphene has Phase 3 clinical data showing testosterone restoration to normal range in 75-80% of hypogonadal men, equivalent testosterone elevation to testosterone gel in controlled comparison, and preservation of LH, FSH, and fertility — the holy grail of male hypogonadism treatment that TRT cannot provide. It failed FDA approval not because it didn't work but because the FDA was not convinced that testosterone elevation alone constituted sufficient patient benefit to justify approval. Development was discontinued in 2021. The compound that arguably best addressed the male hypogonadism treatment gap — raising testosterone endogenously while preserving fertility, with a cleaner isomer profile than racemic clomiphene — never reached the pharmacy shelf. It is now accessed through compounding pharmacies and research chemical vendors. Racemic clomiphene (Clomid), with its accumulated zuclomiphene and associated side effects, remains the most accessible SERM option. The isomer chemistry, the clinical data, and the regulatory failure are all part of the same story.

Check interactions →
Published literature
4human RCTs1human study1animal2in vitro

Counts reflect controlled oral enclomiphene/clomiphene SERM trials in male hypogonadism and fertility-preserving testosterone restoration; no injectable/topical route evidence is implied.

Evidence reality check
Human evidence
5 human studies
4 randomized; 1 observational.
Preclinical base
3 lab signals
1 animal; 2 in-vitro/mechanistic.
Risk posture
No major flags listed
Review route-specific cautions before use.
Categories
Hormonal & HPTALibido & Sexual HealthMuscle & Performance
Properties
WADA S4✓ Human RCTHPTA: stimulatingNot injectable
Half-life
short plasma half-life (estimated ~10-12 hours in humans under repeated dosing)
Evidence
CAnimal replicated
The Isomer Distinction — Why It Matters
Clomiphene (Clomid): racemic 50:50 mixture; widely used off-label for male hypogonadism despite being FDA-approved only for ovulation induction in women. Enclomiphene (trans): pure ER antagonist; short half-life (~hours); responsible for the testosterone-stimulating therapeutic effect; clears rapidly. Zuclomiphene (cis): partial ER agonist; half-life of weeks; accumulates in serum and tissue with repeated racemic clomiphene dosing; responsible for estrogenic side effects in men — gynecomastia, mood effects, visual disturbances (blurred vision, photophobia), and potential suppression of FSH at higher levels. Pure enclomiphene theoretically provides the antagonist benefit (testosterone elevation) without zuclomiphene's estrogenic accumulation — cleaner pharmacological profile with fewer side effects.
The NDA History
Repros Therapeutics filed an NDA for Androxal (enclomiphene citrate 12.5 mg and 25 mg capsules) for secondary hypogonadism in overweight men. Multiple Phase 3 trials completed (including NCT01534208, n=499). Results: testosterone restoration to normal range in 75-80% of men; LH and FSH maintained; fertility preserved. In December 2015, FDA issued a Complete Response Letter — the NDA could not be approved in its present form. Primary FDA concern: while testosterone levels rose, the agency was not convinced this translated to a clear patient benefit (such as improved fertility or symptom scores) that would outweigh potential risks. The FDA recommended additional Phase 3 trials. Repros attempted to comply but development was ultimately discontinued in 2021. Enclomiphene has never been FDA-approved. The compound is accessible as compounded medication or research chemical.
Enclomiphene vs TRT — The Key Distinction
TRT (exogenous testosterone): replaces the testosterone signal but suppresses the HPG axis — LH and FSH fall to near-zero; testicular function ceases; fertility lost; testicular atrophy occurs. Enclomiphene: raises endogenous testosterone via HPG axis stimulation — LH and FSH are maintained or elevated; testicular function preserved; fertility intact. For hypogonadal men concerned about fertility, long-term HPG axis integrity, or who prefer endogenous testosterone production, enclomiphene represents an alternative to exogenous TRT that avoids HPG suppression. The 2025 meta-analysis (Hohl et al., PMC12510335) confirmed no statistically significant difference in total testosterone achieved by SERM therapy vs testosterone gel — with the SERM preserving LH, FSH, and fertility while TRT eliminates them.
Current Status and Access
Not FDA-approved. Not commercially available as Androxal (discontinued 2021). Access paths: (1) Off-label prescribing using racemic clomiphene (Clomid — FDA-approved for female ovulation induction); some prescribers use clomiphene off-label for male hypogonadism with the understanding that enclomiphene is the active testosterone-stimulating isomer. (2) Compounded enclomiphene citrate from 503A compounding pharmacies (requires a prescription; regulatory status evolving). (3) Research chemical market (no prescription; quality verification required). Community and clinic use is substantial, particularly in TRT-adjacent practices.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
LGD-4033 / Ligandrol
C
Same class · Small Molecule

The Most Phase-1-Tested SARM in History. The Problem: Phase 1 Used 0.1-1 mg. The Community Uses 5-20 mg. +1.21 kg Lean Mass at 1 mg in 21 Days. Phase 2 Hip Fracture Trial Positive. HPTA Suppression Dose-Dependent and Documented in Clinical Data. The Dose Gap Between Clinical Trials and Community Use Is the Central Risk Issue. Multiple Elite Athlete Doping Violations Including Canelo Álvarez. WADA S1.2.

Ostarine (MK-2866)
C
Same class · Small Molecule

The Most Clinically Studied SARM. The Phase 3 Trials That Nearly Got It Approved. Why the FDA Said No — and Why It Matters. The Most Modest HPTA Suppression Profile in the SARM Class. The Lowest Hepatotoxicity Signal. The Closest Any SARM Has Come to an FDA Indication. Why Phase 3 Failure Doesn't Mean the Compound Doesn't Work. Jonas Brodin and the NHL Doping Case.

RAD-140 / Testolone
C
Same class · Small Molecule

The Selectivity Claim That Doesn't Hold Up in the Only Published Human Trial. Phase 1 Breast Cancer Study: 59% Elevated AST, 45% Elevated ALT. Six or More Published DILI Case Reports — Including Near-Transplant Cholestatic Hepatitis. HPTA Suppression: As Real as Testosterone. WADA S1.2 Absolute Ban. FDA Warnings. The 53% Problem: Only Half of SARM Products Contain What They Claim. Why 'Fewer Side Effects Than Steroids' Doesn't Mean Safe.

Check interactions